Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Number of Tests Conducted by Technology Types The global sepsis diagnostics market will witness a robust CAGR of 8.7%, valued at $712.74 million in 2021, expected to appreciate and reach $1509.85 million by 2030, confirms Strategic Market Research. North America is envisaged to have the largest market share, followed by Europe. Sepsis is a fatal disease and it occurs when the body's response to a particular infection leads to tissue damage. While bacterial infections are the most prevalent and prominent cause of sepsis, they can also be due to viral infections. Infections of the lungs, stomach, kidneys, and bladder are common. Sepsis can start with a tiny incision that becomes infected or a post-surgery infection. Sepsis can lead to septic shock, multiple organ failure, and death if not recognized and treated promptly. It is estimated that sepsis is present in 30%- 50% of hospitalizations culminating in death. According to the Global Sepsis Alliance, sepsis affects between 47 and 50 million people every year; at least 11 million die – one death every 2.8 seconds. Mortalities vary from 15% to 50%, depending upon the country. High-Risk Groups: Individuals with a weak immune system are more susceptible to sepsis. The factors include: Old age and Infancy. Chronic diseases like Diabetes, kidney or liver disease. Long hospital stays and ICU admission. Use of Invasive devices (like intravenous catheters or breathing tubes). Previous use of antibiotics or corticosteroids. Symptoms: Possible signs and symptoms of sepsis include fever, confusion, difficulty breathing, increased heart rate, and very low blood pressure. Systemic inflammatory response syndrome (SIRS), immunological dysregulation, microcirculatory derangements, and end-organ failure characterize sepsis, a clinical state that accompanies severe infection. Diagnosis: Three ways to diagnose sepsis are- Blood Test: To Assess Evidence of infection, Abnormal liver or kidney function, impaired oxygen availability, clotting Problems and Electrolyte imbalances. Lab Test: Identifies the source of infection in Urine, wound secretion and respiratory secretion. Imaging Tests: These include X-ray for lungs, Ultrasound for gallbladder/kidneys, Computerized Tomography for liver, pancreas or other abdominal organs and Magnetic Resonance Imaging to identify soft tissue or bone infections. Cure: Antibiotics are crucial for treating life-threatening infections, like those that can lead to sepsis. Early intravenous fluid delivery to restore blood pressure, blood volumes, and tissue perfusion remains the standard procedure for severe sepsis and septic shock. The therapeutic intervention involves fluid resuscitation and using of Vasopressors. The Sepsis Treatment market is poised and expected to reach US$1.6Bn by the end of 2030. Key Industry Drivers - Increasing Prevalence of Sepsis & Technological Advancements According to WorldSepsisDay, 47-50 million registered cases of Sepsis occur every year, and 11.2 million die because of Sepsis. This contributes to 20% of global deaths. This rising prevalence is the primary driver for the sepsis diagnostics market growth, and 50% of sepsis death are avoidable provided early detection and proper diagnostics. The awareness and early diagnostics drive by Global Sepsis Alliances has fuelled the market growth for the sepsis diagnostics market because they reduce the mortality rate by 30%. Technological advancements have remarkably enhanced the capabilities of sepsis diagnostics. Newer diagnostic platforms, such as molecular diagnostics, multiplex assays, and point-of-care testing devices, offer rapid and accurate detection of sepsis-causing pathogens and biomarkers. The introduction of automated blood culture systems, next-generation sequencing, and advanced immunoassays has improved sepsis diagnostics' sensitivity, specificity, and efficiency. Acumen Diagnostics has developed AcuSept, a rapid sepsis detection technology that analyses the test sample and gives results in 5 hours. These technological advancements will drive the growth of sepsis diagnostics market. Restraints - High Cost and Lack of Skilled Practitioners High treatment costs: The cost of sepsis management in US hospitals ranks highest among admissions for all disease states. According to estimates by The Society of Critical Care Medicine (SCCM), the last decade witnessed that sepsis accounted for more than $24 billion in hospital expenses, representing 13% of total US hospital costs, but accounted for only 3.6% of hospital stays. Severe sepsis, Sepsis without organ dysfunction and septic shock were associated with 15%, 6%, and 34% mortality rates and costs of approximately $16,000, $38,000, and $25,000, respectively, Lack of skilled practitioners: Most clinical practitioners and emergency physicians outside intensive care medicine are unfamiliar with sepsis. The lack of sepsis education is a primary challenge in sepsis management. Opportunities Low Immunity among the Population: Sepsis has a high prevalence rate among the old age and neonatal population, owing to their weak immunity. An increase in the old age population will drive the incidence rate of sepsis. As per the World Population Ageing 2019, the number of people aged 65 years or over will double in the coming 30 years, while the number of persons aged 80 years or over will increase threefold. Government Support: The CDC focuses on five critical aspects of sepsis: Engaging clinical professional groups and patient advocates to raise sepsis awareness. To increase early recognition of sepsis, align infection prevention, chronic illness management, and optimal antibiotic usage. The government is also raising funds and creating awareness about sepsis. The 17th World Health Assembly recently adopted Resolution WHA 70.7 on Improving the prevention, diagnosis, and clinical management of sepsis. Novel Biomarkers: Currently, novel biomarkers for sepsis diagnosis are evolving. The rising prevalence of sepsis and infectious disorders is predicted to drive the need for novel diagnostic solutions. As per the article published in Infection & Chemotherapy Journal, biomarkers can be used for risk stratification, monitoring of treatment responses, diagnosis and outcome prediction. Procalcitonin, C- Reactive Protein, different cytokines, and cell surface markers are among the more than 170 biomarkers that have been found useful for evaluating sepsis. High Revenue per Patient: The average cost per hospital stay for sepsis is twice that of all other diseases. And sepsis is the leading cause of hospital readmission, costing more than $3.5 billion within the US. As per a new study published in CHEST Journal, the estimated annual cost of sepsis readmissions is almost half or 50% of all the four conditions in the Medicare's Hospital Readmissions Reduction Program (HRRP) which includes acute myocardial infarction, pneumonia, chronic obstructive pulmonary disease and congestive heart failure. The rising bloodstream infections will lead to increased adoption of sepsis diagnostic products. Sepsis Diagnostics Market Analysis Of Different Segments Covered in the Report Based on Technology Molecular Diagnostics Immunoassay Microbiology Other Technologies Based on Product Assays and Reagents Blood Culture Media Instruments Software Products Based on Diagnostic Methods Automated Diagnostics Conventional Diagnostics Based on Pathogens Fungal Sepsis Bacterial Sepsis Other Pathogens Based on Testing Type POC testing Laboratory testing Based on End-User Hospital Laboratories Reference Laboratories Others Regional Coverage Analysis North America Asia -Pacific Europe Middle-East and Africa South America Segments Analysis & Insights By Technology, the sepsis diagnostics market is categorized into molecular diagnostics, immunoassay, microbiology, and other technologies based on technology. The molecular diagnostics segment is leading the market with a market value of $10 billion in 2023 and is projected to grow by a CAGR of 8%. Molecular diagnostics has proven to be a superior methodology for diagnosing diseases more quickly and with little complexity. There is a greater demand for these procedures, particularly for diagnosing infectious diseases. The need for molecular diagnosis is increased due to the rise in the ubiquity of infectious diseases in developed and developing countries. Major bacterial and viral outbreaks in the Middle East and Africa compelled all governments and academic institutions to adopt molecular diagnostic methods to stop the microbial outbreaks. A recent study suggested that 25% of deaths worldwide are due to infectious diseases. To tackle this, many governments have primarily focused on molecular diagnosis, and this is proliferating the molecular diagnostics segment. The Microbiology segment is estimated to show the fastest growth due to their direct methods of identifying the cause of infection by cultures, microscopy, antigen detection, and specific gene detection. According to SMR, the immunoassay is expected to grow by a CAGR of 7.5% due rise of cancer in old age people. By Product, The market is cataloged as assays and reagents, blood culture media, instruments, and software products on the basis of products. The Blood culture media is leading the industry with a market share of 40% and a market value of $5 billion in 2023 and is expected to appreciate the rising prevalence of Sepsis. Healthcare providers prefer blood culture testing for convenience, cost-effective testing methods, and rapid diagnostic techniques. Software products are growing due to the adoption of automation and better management of Sepsis on a large scale. HCA created the Sepsis Prediction and Optimization of Therapy (SPOT) platform to gather and analyze clinical data and alert healthcare providers in real time. They used Red Hat open-source software to create a PaaS foundation and used automation & analytics software to support real-time data collection, analysis, & notification processes. By Diagnostic Method, the Conventional technique was the highest revenue-grossing segment. The conventional technique provided the highest revenue due to its extensive use by hospitals, independent clinical laboratories, and pathology laboratories. Automated Diagnostics is becoming popular as it has a quicker yield and great sensitivity than the conventional technique. By Pathogen, the sepsis diagnostics market is categorized into Fungal Sepsis, Bacterial Sepsis, and Other Pathogens. The bacterial sepsis segment holds the largest market share at 80% due to antimicrobial resistance. UK government has announced £39 million for antimicrobial resistance research. A study published by CDC reported that sepsis incidence and mortality rates increase with age, with the highest rates observed among the elderly population. According to a study published by the sepsis alliance, immunocompromised patients have a higher risk of Sepsis and increased mortality than immunocompetent individuals. By Region, North America is poised to lead the Global Sepsis Diagnostics Market share, owing to the region's high sepsis prevalence rate, adoption of sophisticated procedures, and well-established healthcare infrastructure. Europe is the biggest and the largest sepsis detection device market because of the high prevalence of the disease, which accounts to nearly 3 in 1,000 among the general population and 23 in 1,000 in hospitalized patients and a very high mortality rate hovering between 36,000-64,000 cases in Wales and England. The Asia Pacific is poised to exhibit the fastest growth, owing to increasing expenditure on R&D activities, rising aged population, and poor hygiene conditions in many underdeveloped regions. According to WHO’s first Global Report on the Epidemiology and Burden of Sepsis 2020, Sepsis disproportionately affects people in low- and middle-income countries. Antibiotic resistance limits the ability to treat and manage sepsis. By Testing Type, the sepsis diagnostics market is categorized into POC and Laboratory testing. Laboratory testing has the lion's share of 70% in the sepsis diagnostics market due to high accuracy and comprehensive analysis of the patient. Laboratory testing methods in sepsis diagnostics have benefited from technological advancements, improving accuracy, efficiency, and turnaround time. For example, introducing automated blood culture systems and molecular diagnostic platforms has streamlined testing. The Clinical and Laboratory Standards Institute (CLSI) issues guidelines for laboratory testing procedures, ensuring standardization and quality control in sepsis diagnostics. In the case of POC testing, it saves 1 hour of testing time compared to laboratory testing and is 40% cheaper than laboratory testing. Sepsis POC diagnostics are a potential remedy for risk-stratifying new patients, directing initial treatment, tracking the progression of infection, and assessing patients' response to treatment. By End-use, Hospital Laboratories are the largest grossing segment because of the rising number of hospital-acquired infections (HAIs). According to the WHO, ICU-acquired infections, such as surgical-site wound infections and UTI’s, are two to three times greater in number in the developing nations as compared to developed countries. Reference laboratories are the fastest-growing segment because they are equipped with cutting-edge diagnostic techniques that provide more precise, reliable, and timely results. Moreover, they receive Orders for Blood culture tests Outsourced by Hospitals. Sepsis Diagnostics Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 Market size value in 2021 USD 712.74 Million Revenue forecast in 2030 USD 1509.85 Million Growth rate CAGR of 8.70% The base year for estimation 2021 Historical data 2017 – 2021 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Technology, By Product, By Diagnostic Methods, By Pathogen, By Testing Types, By End-user and By Region. By Technology Molecular Diagnostics, Immunoassay, Microbiology, and Other Technologies By Product Instruments, Assays and Reagents, Blood Culture Media and Other Products By Diagnostic Methods Automated Diagnostics and Conventional Diagnostics By Pathogens Fungal Sepsis, Bacterial Sepsis, and Other Pathogens By Testing Types Laboratory testing and POC testing By End-User Hospital Laboratories, Reference Laboratories and Others By Region North America, Asia-Pacific, Europe, Middle-East and Africa, and South America Country Scope US, Mexico, Germany, Mexico, UK, France, Japan, China, India etc. Company Usability Profiles bioMérieux SA, Becton, Dickinson and Company,Thermo Fisher Scientific, Inc.,F. Hoffmann-La Roche AG, Luminex Corporation, Danaher Corporation (Beckman Coulter, Inc.), Bruker Corporation, Wolters Kluwer NV, Amara Health Analytics, Cerner Corporation, Epic Systems Corporation, Mckesson Corporation, GE Healthcare, and Koninklijke Philips N.V. Sepsis Diagnostics Market Competitive Landscape Analysis Global Sepsis Diagnostics Market Report contains a thorough competitive landscape analysis, which outlines the most pertinent competitors operating in the global market. The comparison is based on market initiatives, overall revenue generation, company overview, production analysis, value chain optimization, R&D investment, market share financials, company strengths and weaknesses, production capacity, market potential, production sites and facilities, and other variables. BioMérieux SA Becton, Dickinson and Company Thermo Fisher Scientific, Inc. F. Hoffmann-La Roche AG Danaher Corporation (Beckman Coulter, Inc.) Bruker Corporation Luminex Corporation Wolters Kluwer NV. Amara Health Analytics GE Healthcare Epic Systems Corporation Mckesson Corporation Cerner Corporation Koninklijke Philips N.V. Recent Developments On May 2023, BD announced the 510(k) clearance from FDA for the BD KiestraTM MRSA imaging application, which uses AI to interpret bacterial growth and release negative specimens with minimal human interaction. BD SynapsysTM Informatics Solution is an AI-based imaging application that helps use limited laboratory staff more efficiently and allows lab personnel to bring their expertise to bear on more complex specimens. This minimizes the risk of Sepsis. On March 2023, Proxim Diagnostics Corp. developed a handheld POC diagnostic device and received an investment of $3 million from bioMérieux. This handheld device is fully automatic and has the potential to run numerous multiplexed assays with disposable cartridges. Proxim is developing several immunoassays for Sepsis, cardiology, and infectious disease that can provide the same sensitivity and precision as tests run on larger, centralized laboratory equipment. Various Products that Key Market Leaders Develop: Product Function Key players BACT/ALERT 3D Automated Microbial Detection Systems for septicemia diagnosis using unique colorimetry technology that reduces false negatives due to delayed bottle entry. BioMerieux B.R.A.H.M.S PCT Point-of-care (POC) rapid procalcitonin assay blood test which allows fast diagnosis of bacterial infections and sepsis. The assay is designed to measure procalcitonin (PCT) Thermo Fisher Scientific ePlex Blood Culture Identification (BCID) Panels Claims that 95% of currently identified bloodstream infections can be detected early. Hoffmann-La Roche AG VERIGENE System It accurately and swiftly identifies and detects infectious pathogens and their associated drug resistance marker-rather than relying on time consuming culture methods. Luminex Corporation Frequently Asked Question About This Report How big is the sepsis diagnostics market? The global sepsis diagnostics market size was $712.74 million in 2021 and is expected to reach a value of $1509.85 million by 2030. What is the sepsis diagnostics market growth? The global sepsis diagnostics market is expected to grow at a compound annual growth rate (CAGR) of 8.7% from 2021 to 2030 to reach USD 1509.85 million by 2030. Which region had the maximum amount of share in the market? North America had the maximum share in the global sepsis diagnostics market. Which segment among the sepsis diagnostics product market provides the most opportunity for growth? Sepsis Diagnostics Market forecasts that the assays and Reagents segment is projected to show lucrative growth due to new diagnostic capability and the installation of automated testing facilities. Which segment among the sepsis diagnostics technology market provides the most opportunity for growth? On doing sepsis diagnostics market analysis, the molecular diagnostics segment will show the fastest growth due to its increasing adoption of molecular diagnostic technology. Sources https://www.global-sepsis-alliance.org/sepsis https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2724768 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2043413/ https://www.cdc.gov/hai/pdfs/progress-report/hai-progress-report.pdf https://www.jwatch.org/na48114/2019/01/02/epidemiology-and-costs-sepsis-us https://www.who.int/activities/improving-the-prevention-diagnosis-and-clinical-management-of-sepsis https://pubmed.ncbi.nlm.nih.gov/11640135/ https://news.bd.com/2023-05-16-BD-Gains-510-k-Clearance-of-Artificial-Intelligence-Software-for-MRSA-Diagnostics https://www.cdc.gov/nchs/data/databriefs/db422.pdf https://www.gov.uk/government/news/39-million-for-amr-research-as-uk-launches-global-health-framework https://www.sepsis.org/sepsisand/impaired-immune-system/ https://www.ncbi.nlm.nih.gov/pmc/ https://www.spandidos-publications.com/10.3892/mmr.2023.12991 https://www.redhat.com/en/success-stories/hca-healthcare https://www.worldsepsisday.org/sepsisfacts 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Sepsis Diagnostics Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Sepsis Diagnostics Market 4.2.1 market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 market, by region, 2021 - 2030 (USD Million) 4.4 By Product Business Analysis 4.4.1 market, By Product, 2021 - 2030 (USD Million) 4.5 By Technology Business Analysis 4.5.1 market, By Technology, 2021 - 2030 (USD Million) 4.6 Diagnostic Methods Business Analysis 4.6.1 market, By Diagnostic Methods, 2021 - 2030 (USD Million) 4.7 End-user Business Analysis 4.7.1 market, By End-user, 2021 - 2030 (USD Million) 4.8 Pathogens Analysis 4.8.1 market, By Pathogens, 2021 - 2030 (USD Million) 4.9 Testing Type Analysis 4.9.1 market, By Testing Type, 2021 - 2030 (USD Million) 4.10 Value Chain Analysis 4.11 Market Variable Analysis 4.11.1 Market Drivers Analysis 4.11.2 Market Restraints Analysis 4.12 Business Environment Analysis Tool 4.12.1 market PEST analysis 4.12.2 market Porter’s analysis 4.13 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. End-user Analysis 5.11.1. Trends in End-user (2014-2021) 5.11.2. Trends in End-user (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Product 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Product Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Assays and Reagents 7.3.1. Assays and Reagents market, 2021 - 2030 (USD Million) 7.4. Blood Culture Media 7.4.1. Blood Culture Media market, 2021 - 2030 (USD Million) 7.5. Instruments 7.5.1. Instruments market, 2021 - 2030 (USD Million) 7.6. Software Products 7.6.1. Software Products market, 2021 - 2030 (USD Million) 8. Market: By Technology Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Molecular Diagnostics 8.3.1. Molecular Diagnostics market, 2021 - 2030 (USD Million) 8.4. Immunoassay 8.4.1. Immunoassay market, 2021 - 2030 (USD Million) 8.5. Microbiology 8.5.1. Microbiology market, 2021 - 2030 (USD Million) 8.6. Other Technologies 8.6.1. Other Technologies market, 2021 - 2030 (USD Million) 9. Market: By Diagnostic Methods Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Automated Diagnostics 9.3.1. Automated Diagnostics market, 2021 - 2030 (USD Million) 9.4. Conventional Diagnostics 9.4.1. Conventional Diagnostics market, 2021 - 2030 (USD Million) 10. Market: By End-user Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. Hospital Laboratories 10.3.1. Hospital Laboratories market, 2021 - 2030 (USD Million) 10.4. Reference Laboratories 10.4.1. Reference Laboratories market, 2021 - 2030 (USD Million) 10.5. Others 10.5.1. Others market, 2021 - 2030 (USD Million) 11. Market: By Pathogens Segment Analysis 11.1. Introduction 11.2. Sales Volume & Revenue Analysis (2021-2030) 11.3. Fungal Sepsis 11.3.1. Fungal Sepsis market, 2021 - 2030 (USD Million) 11.4. Bacterial Sepsis 11.4.1. Bacterial Sepsis market, 2021 - 2030 (USD Million) 11.5. Other Pathogens 11.5.1. Other Pathogens market, 2021 - 2030 (USD Million) 12. Market: By Testing Type Segment Analysis 12.1. Introduction 12.2. Sales Volume & Revenue Analysis (2021-2030) 12.3. POC testing 12.3.1. POC testing market, 2021 - 2030 (USD Million) 12.4. Laboratory testing 12.4.1. Laboratory testing market, 2021 - 2030 (USD Million) 13. Market: Regional Outlook 13.1 North America 13.1.1. North America market, By Product, 2021 - 2030 (USD Million) 13.1.2. North America market, By Technology, 2021 - 2030 (USD Million) 13.1.3. North America market, by End-user, 2021 - 2030 (USD Million) 13.1.4. North America market, by Testing Type, 2021 - 2030 (USD Million) 13.1.5. North America market, by Pathogens, 2021 - 2030 (USD Million) 13.1.6. North America market, by Country, 2021 - 2030 (USD Million) 12.1.4.1. U.S. 12.1.4.1.1. U.S. market, By Product, 2021 - 2030 (USD Million) 12.1.4.1.2. U.S. market, By Technology, 2021 - 2030 (USD Million) 12.1.4.1.3. U.S. market, by End-user, 2021 - 2030 (USD Million) 12.1.4.1.4. U.S. market, by Testing Type, 2021 - 2030 (USD Million) 12.1.4.1.5. U.S. market, by Pathogens, 2021 - 2030 (USD Million) 12.1.4.1.6. U.S. market, by Country, 2021 - 2030 (USD Million) 12.1.4.2. Canada 12.1.4.2.1. Canada market, By Product, 2021 - 2030 (USD Million) 12.1.4.2.2. Canada market, By Technology, 2021 - 2030 (USD Million) 12.1.4.2.3. Canada market, by End-user, 2021 - 2030 (USD Million) 12.2. Europe 12.2.1. Europe market, By Product, 2021 - 2030 (USD Million) 12.2.2. Europe market, By Technology, 2021 - 2030 (USD Million) 12.2.3. Europe market, by End-user, 2021 - 2030 (USD Million) 12.2.4. Europe market, by Testing Type, 2021 - 2030 (USD Million) 12.2.5. Europe market, by Pathogens, 2021 - 2030 (USD Million) 12.2.6. Europe market, by country, 2021 - 2030 (USD Million) 12.2.4.1 U.K. 12.2.4.1.1. U.K. market, By Product, 2021 - 2030 (USD Million) 12.2.4.1.2. U.K. market, By Technology, 2021 - 2030 (USD Million) 12.2.4.1.3. U.K. market, by End-user, 2021 - 2030 (USD Million) 12.2.4.2. Germany 12.2.4.2.1. Germany market, By Product, 2021 - 2030 (USD Million) 12.2.4.2.2. Germany market, By Technology, 2021 - 2030 (USD Million) 12.2.4.2.3. Germany market, by End-user, 2021 - 2030 (USD Million) 12.2.4.3. France 12.2.4.3.1. France market, By Product, 2021 - 2030 (USD Million) 12.2.4.3.2. France market, By Technology, 2021 - 2030 (USD Million) 12.2.4.3.3. France market, by End-user, 2021 - 2030 (USD Million) 12.2.4.4. Rest of Europe 12.2.4.4.1. Rest of Europe market, By Product, 2021 - 2030 (USD Million) 12.2.4.4.2. Rest of Europe market, By Technology, 2021 - 2030 (USD Million) 12.2.4.4.3. Rest of Europe market, by End-user, 2021 - 2030 (USD Million) 12.3. Asia Pacific 12.3.1. Asia Pacific market, By Product, 2021 - 2030 (USD Million) 12.3.2. Asia Pacific market, By Technology, 2021 - 2030 (USD Million) 12.3.3. Asia Pacific market, by End-user, 2021 - 2030 (USD Million) 12.3.4. Asia Pacific market, by Testing Type, 2021 - 2030 (USD Million) 12.3.5. Asia Pacific market, by Pathogens, 2021 - 2030 (USD Million) 12.3.6. Asia Pacific market, by country, 2021 - 2030 (USD Million) 12.3.4.1. China 12.3.4.1.1. China market, By Product, 2021 - 2030 (USD Million) 12.3.4.1.2. China market, By Technology, 2021 - 2030 (USD Million) 12.3.4.1.3. China market, by End-user, 2021 - 2030 (USD Million) 12.3.4.2. India 12.3.4.2.1. India market, By Product, 2021 - 2030 (USD Million) 12.3.4.2.2. India market, By Technology, 2021 - 2030 (USD Million) 12.3.4.2.3. India market, by End-user, 2021 - 2030 (USD Million) 12.3.4.3. Japan 12.3.4.3.1. Japan market, By Product, 2021 - 2030 (USD Million) 12.3.4.3.2. Japan market, By Technology, 2021 - 2030 (USD Million) 12.3.4.3.3. Japan market, by End-user, 2021 - 2030 (USD Million) 12.3.4.4. South Korea 12.3.4.4.1. South Korea market, By Product, 2021 - 2030 (USD Million) 12.3.4.4.2. South Korea market, By Technology, 2021 - 2030 (USD Million) 12.3.4.4.3. South Korea market, by End-user, 2021 - 2030 (USD Million) 12.3.4.5. Rest of ASIA PACIFIC 12.3.4.5.1. Rest of ASIA PACIFIC market, By Product, 2021 - 2030 (USD Million) 12.3.4.5.2. Rest of ASIA PACIFIC market, By Technology, 2021 - 2030 (USD Million) 12.3.4.5.3. Rest of ASIA PACIFIC market, by End-user, 2021 - 2030 (USD Million) 12.4. Latin America 12.4.1. Latin America market, By Product, 2021 - 2030 (USD Million) 12.4.2. Latin America market, By Technology, 2021 - 2030 (USD Million) 12.4.3. Latin America market, by End-user, 2021 - 2030 (USD Million) 12.4.4. Latin America market, by Testing Type, 2021 - 2030 (USD Million) 12.4.5. Latin America market, by Pathogens, 2021 - 2030 (USD Million) 12.4.6. Latin America market, by Diagnostic Methods, 2021 - 2030 (USD Million) 12.4.7. Latin America market, by country, 2021 - 2030 (USD Million) 12.4.4.1. Brazil 12.4.4.1.1. Brazil market, By Product, 2021 - 2030 (USD Million) 12.4.4.1.2. Brazil market, By Technology, 2021 - 2030 (USD Million) 12.4.4.1.3. Brazil market, by End-user, 2021 - 2030 (USD Million) 12.4.4.2. Mexico 12.4.4.2.1. Mexico market, By Product, 2021 - 2030 (USD Million) 12.4.4.2.2. Mexico market, By Technology, 2021 - 2030 (USD Million) 12.4.4.2.3. Mexico market, by End-user, 2021 - 2030 (USD Million) 12.4.4.3. Rest of Latin America 12.4.4.3.1. Rest of the Latin America market, By Product, 2021 - 2030 (USD Million) 12.4.4.3.2. Rest of the Latin America market, By Technology, 2021 - 2030 (USD Million) 12.4.4.3.3. Rest of the Latin America market, by End-user, 2021 - 2030 (USD Million) 12.5. MEA 12.5.1. MEA market, By Product, 2021 - 2030 (USD Million) 12.5.2. MEA market, By Technology, 2021 - 2030 (USD Million) 12.5.3. MEA market, by End-user, 2021 - 2030 (USD Million) 12.5.4. MEA market, by Diagnostic Methods, 2021 - 2030 (USD Million) 12.5.4. MEA market, by Testing Type, 2021 - 2030 (USD Million) 12.5.4. MEA market, by region, 2021 - 2030 (USD Million) 13. Competitive Landscape 13.1 BioMérieux SA 13.1.1. Company overview 13.1.2. Financial performance 13.1.3. Product Portfolio Analysis 13.1.4. Business Strategy & Recent Development 13.2. Becton, Dickinson and Company 13.2.1. Company overview 13.2.2. Financial performance 13.2.3. Product Portfolio Analysis 13.2.4. Business Strategy & Recent Development 13.3. THERMO FISHER SCIENTIFIC, INC. 13.3.1. Company overview 13.3.2. Financial performance 13.3.3. Product Portfolio Analysis 13.3.4. Business Strategy & Recent Development 13.4. F. Hoffmann-La Roche AG. 13.4.1. Company overview 13.4.2. Financial performance 13.4.3. Product Portfolio Analysis 13.4.4. Business Strategy & Recent Development 13.5. Danaher Corporation (Beckman Coulter, Inc.). 13.5.1. Company overview 13.5.2. Financial performance 13.5.3. Product Portfolio Analysis 13.5.4. Business Strategy & Recent Development 13.6. Bruker Corporation 13.6.1. Company overview 13.6.2. Financial performance 13.6.3. Product Portfolio Analysis 13.6.4. Business Strategy & Recent Development 13.7. Luminex Corporation 13.7.1. Company overview 13.7.2. Financial performance 13.7.3. Product Portfolio Analysis 13.7.4. Business Strategy & Recent Development 13.8. Wolters Kluwer NV 13.8.1. Company overview 13.8.2. Financial performance 13.8.3. Product Portfolio Analysis 13.8.4. Business Strategy & Recent Development 13.9. AMARA HEALTH ANALYTICS. 13.9.1. Company overview 13.9.2. Financial performance 13.9.3. Product Portfolio Analysis 13.9.4. Business Strategy & Recent Development 13.10. GE Healthcare 13.10.1. Company overview 13.10.2. Financial performance 13.10.3. Product Portfolio Analysis 13.10.4. Business Strategy & Recent Development 13.11. Epic Systems Corporation 13.11.1. Company overview 13.11.2. Financial performance 13.11.3. Product Portfolio Analysis 13.11.4. Business Strategy & Recent Development 13.12. Mckesson Corporation 13.12.1. Company overview 13.12.2. Financial performance 13.12.3. Product Portfolio Analysis 13.12.4. Business Strategy & Recent Development 13.13. Cerner Corporation 13.13.1. Company overview 13.13.2. Financial performance 13.13.3. Product Portfolio Analysis 13.13.4. Business Strategy & Recent Development 13.14. Koninklijke Philips N.V. 13.14.1. Company overview 13.14.2. Financial performance 13.14.3. Product Portfolio Analysis 13.14.4. Business Strategy & Recent Development List of Tables (77 Tables) TABLE 1. MARKET, By Product, 2021-2030 (USD Million) TABLE 2. MARKET FOR Assays and Reagents, BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR Blood Culture Media, BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR Instruments, BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET FOR Software Products, BY REGION, 2021-2030 (USD Million) TABLE 6. MARKET, By Technology, 2021-2030 (USD Million) TABLE 7. MARKET FOR Molecular Diagnostics, BY REGION, 2021-2030 (USD Million) TABLE 8. MARKET FOR Immunoassay, BY REGION, 2021-2030 (USD Million) TABLE 9. MARKET FOR Microbiology, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET FOR Other Technologies, BY REGION, 2021-2030 (USD Million) TABLE 11. MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 12. MARKET FOR Hospital Laboratories, BY REGION, 2021-2030 (USD Million) TABLE 13. MARKET FOR Reference Laboratories, BY REGION, 2021-2030 (USD Million) TABLE 14. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 15. MARKET, By Diagnostic Methods, 2021-2030 (USD Million) TABLE 16. MARKET FOR Automated Diagnostics, BY REGION, 2021-2030 (USD Million) TABLE 17. MARKET FOR Conventional Diagnostics, BY REGION, 2021-2030 (USD Million) TABLE 18. MARKET, By Pathogens, 2021-2030 (USD Million) TABLE 19. MARKET FOR Fungal Sepsis, BY REGION, 2021-2030 (USD Million) TABLE 20. MARKET FOR Bacterial Sepsis, BY REGION, 2021-2030 (USD Million) TABLE 21. MARKET FOR Other Pathogens, BY REGION, 2021-2030 (USD Million) TABLE 22. MARKET, By Testing Type, 2021-2030 (USD Million) TABLE 23. MARKET FOR POC testing, BY REGION, 2021-2030 (USD Million) TABLE 24. MARKET FOR Laboratory testing, BY REGION, 2021-2030 (USD Million) TABLE 25. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 26. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 27. NORTH AMERICA MARKET, By Product, 2021-2030 (USD Million) TABLE 28. NORTH AMERICA MARKET, By Technology, 2021-2030 (USD Million) TABLE 29. NORTH AMERICA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 30. NORTH AMERICA MARKET, BY Testing Type, 2021-2030 (USD Million) TABLE 31. NORTH AMERICA MARKET, BY Pathogens, 2021-2030 (USD Million) TABLE 32. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 33. EUROPE MARKET, By Product, 2021-2030 (USD Million) TABLE 34. EUROPE MARKET, By Technology, 2021-2030 (USD Million) TABLE 35. EUROPE MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 36. EUROPE MARKET, BY Testing Type, 2021-2030 (USD Million) TABLE 37. EUROPE MARKET, BY Pathogens, 2021-2030 (USD Million) TABLE 38. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 39. ASIA-PACIFIC MARKET, By Product, 2021-2030 (USD Million) TABLE 40. ASIA-PACIFIC MARKET, By Technology, 2021-2030 (USD Million) TABLE 41. ASIA-PACIFIC MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 42. ASIA-PACIFIC MARKET, BY Testing Type, 2021-2030 (USD Million) TABLE 43. ASIA-PACIFIC MARKET, BY Pathogens, 2021-2030 (USD Million) TABLE 44. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 45. LAMEA MARKET, By Product, 2021-2030 (USD Million) TABLE 46. LAMEA MARKET, By Diagnostic Methods, 2021-2030 (USD Million) TABLE 47. LAMEA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 48. LAMEA MARKET, BY Testing Type, 2021-2030 (USD Million) TABLE 49. LAMEA MARKET, BY Pathogens, 2021-2030 (USD Million) TABLE 50. BioMérieux SA: COMPANY SNAPSHOT TABLE 51. BioMérieux SA: OPERATING SEGMENTS TABLE 52. Becton, Dickinson and Company: COMPANY SNAPSHOT TABLE 53. Becton, Dickinson and Company: OPERATING SEGMENTS TABLE 54. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT TABLE 55. THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS TABLE 56. F. Hoffmann-La Roche AG.: COMPANY SNAPSHOT TABLE 57. F. Hoffmann-La Roche AG.: OPERATING SEGMENTS TABLE 58. Danaher Corporation (Beckman Coulter, Inc.).: COMPANY SNAPSHOT TABLE 59. Danaher Corporation (Beckman Coulter, Inc.).: OPERATING SEGMENTS TABLE 60. Bruker Corporation: COMPANY SNAPSHOT TABLE 61. Bruker Corporation: OPERATING SEGMENTS TABLE 62. Luminex Corporation: COMPANY SNAPSHOT TABLE 63. Luminex Corporation: OPERATING SEGMENTS TABLE 64. Wolters Kluwer NV: COMPANY SNAPSHOT TABLE 65. Wolters Kluwer NV: OPERATING SEGMENTS TABLE 66. AMARA HEALTH ANALYTICS.: COMPANY SNAPSHOT TABLE 67. AMARA HEALTH ANALYTICS.: OPERATING SEGMENTS TABLE 68. GE Healthcare: COMPANY SNAPSHOT TABLE 69. GE Healthcare: OPERATING SEGMENTS TABLE 70. Epic Systems Corporation: COMPANY SNAPSHOT TABLE 71. Epic Systems Corporation: OPERATING SEGMENTS TABLE 72. Mckesson Corporation: COMPANY SNAPSHOT TABLE 73. Mckesson Corporation: OPERATING SEGMENTS TABLE 74. Cerner Corporation: COMPANY SNAPSHOT TABLE 75. Cerner Corporation: OPERATING SEGMENTS TABLE 76. Koninklijke Philips N.V.: COMPANY SNAPSHOT TABLE 77. Koninklijke Philips N.V.: OPERATING SEGMENTS List of Figures (26 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 14 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for Sepsis Diagnostics Market, By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for Sepsis Diagnostics Market, By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market Share, By Technology, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By End-user, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Product, 2019 vs. 2025 (USD Million) Figure 14 Market Share, By Pathogens, 2019 vs. 2025 (USD Million) Figure 15 Market Share, By Diagnostic Methods, 2019 vs. 2025 (USD Million) Figure 16 Market Share, By Testing Type, 2019 vs. 2025 (USD Million) Figure 17 Geographical Snapshot of the Market Figure 18 Blood Culture Media to Witness Higher CAGR in Market for Product Segment during Forecast Period. Figure 19 Conventional Diagnosticsto Witness Higher CAGR in Market for Diagnostic Methods Segment during Forecast Period. Figure 20 Bacterial Sepsis to Witness Higher CAGR in Market for Pathogens Segment during Forecast Period. Figure 21 Microbiology to Witness Higher CAGR in the Market for Technology Segment during Forecast Period. Figure 22 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 23 Market: Drivers, Restraints, Opportunities, and Challenges Figure 24 North America: Market Snapshot Figure 25 Asia Pacific: Market Snapshot Figure 26 Vendor Dive: Evaluation Overview